301 An analysis of medical resource utilisation (MRU) associated with hospitalised pulmonary exacerbations (PulmEx) in the DPM-CF-301 and DPM-CF-302 registration trials of inhaled mannitol (Bronchitol®) in patients with cystic fibrosis (CF)  by Toward, T.J. et al.
Posters 14. Delivery of care S125
299 The impact of transition on patient adherence to nebuliser
therapy
J. Park1, P. McCormack2, E.A. Lloyd1, A. Pitman2, K.W. Southern3, M. Walshaw4,
P.S. McNamara3. 1Liverpool Heart and Chest NHS Foundation Trust,
Physiotherapy, Liverpool, United Kingdom; 2Alder Hey Children’s NHS Foundation
Trust, Physiotherapy, Liverpool, United Kingdom; 3Alder Hey Children’s NHS
Foundation Trust, Regional CF Unit, Liverpool, United Kingdom; 4Liverpool
Heart and Chest NHS Foundation Trust, Regional CF Unit, Liverpool, United
Kingdom
Objectives: In CF patients of all ages, aerosolised medications are established treat-
ments for chronic airway infection, inﬂammation and to improve airway clearance.
Maintaining adherence to these therapies can be a challenge, particularly during
adolescence and early adulthood. We hypothesised that adherence to nebulised
therapies decreased after paediatric patients transitioned to adult care. In this study
we examined adherence to nebulised therapy in the year pre- and post-transfer to
adult centre.
Method: Patients were identiﬁed who had transferred from the regional paediatric
to the regional adult service in Liverpool and who had been prescribed nebulised
anti-pseudomonal medication via breath-activated data logging nebulisers (I-Neb™)
for a least a year pre- and post-transition. Adherence (% of doses taken ÷
expected number) was calculated for the year before and the year following transfer.
Treatment times were also analysed.
Results: 19 patients have been identiﬁed; to date, data from 8 patients have been
analysed. The number of daily medications ranged from once to three times daily.
Mean (SD) adherence in the 6 months prior to transfer (57 (38)%) was signiﬁcantly
greater than adherence in the 6 months following transfer (28 (23)%: p = 0.011);
there was a similar trend when adherence in the 12 months pre/post transfer was
analysed. Treatment times remained unchanged.
Conclusion: Adherence to nebulisation decreased signiﬁcantly in this group of
patients following transfer. Further studies are needed to ascertain what factors
contribute to the change in adherence following transition and how best to support
these young people in maintaining adherence into adulthood.
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Previous audit (currently submitted) showed that the oxygen service at the All
Wales Adult CF Centre did not meet guidelines set for COPD patients by the
British Thoracic Society Working Group on Home Oxygen Services. Following
this our service was revised to address this and ensure a safe and cost effective
service.
Objectives: Assess the impact of the service changes by
i. re-auditing against guidelines
ii. detailed review of oxygen therapy concordance.
Methods: Retrospective data was collected from home oxygen order forms, medical
notes, Air Products (oxygen provider) and phone interviews with patients. Data
collected: age; sex; FEV1; oxygen assessment and prescription; follow up; oxygen
usage; reasons for compliance variation.
Results: 15 of our 239 (6%) patients receive home oxygen (mean age 33.1 years,
SD 10.8; mean predicted percentage FEV1 31.5%, SD 11.7). 12 are prescribed
overnight oxygen, 11 ambulatory oxygen and 2 SBOT. All patients had appropriate
oxygen assessment. Those with a new oxygen prescription received a home visit
within 4 weeks and had specialist follow up within 3 months of installation. Air
products data showed oxygen was under used by 69%, correctly used by 19%
and over used by 13%. Close review of the data and patient interviews identiﬁed
no conerns with SBOT or overnight oxygen use but that 13% were under using
ambulatory oxygen. Variation was due to hospital admissions, dual oxygen supply,
recent transplant and supply of oxygen to be used only during chest exacerbations.
Conclusion: This re-audit shows the service is now in line with the guidelines.
It highlights the beneﬁt of reviewing compliance data in conjunction with patient
interviews.
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PulmEx cause signiﬁcant anxiety to CF patients and their carers. Clinically,
PulmEx are associated with an accelerated lung function decline, increased risk
of reoccurrence, early lung transplantation and death. On average UK patients
experience ~1.5 PulmEx per year, however many occur to the same patients. PulmEx
cause signiﬁcant economic burden to strained healthcare systems. To quantify this
impact, medical resource utilisation (MRU) was examined in (pooled) adult patients
from the Bronchitol® registration trials.
Patient medical records, discharge summaries and diaries were assessed and
concomitant medication use (start/stop dates, daily dose, route and indication)
prescribed for: anti-infection, respiratory system or reasons termed: “CF”, “ﬁbro-
sis”, “CF-related” were collected. Details of attendance, treating medical facility
and community healthcare professional visits were also captured. Unit-costs were
derived from national reference sources (2011−12) and applied at a patient-level.
Protocol-deﬁned Fuch’s criteria objectively assessed hospitalised events (PulmEx)
in the studies. MRU was considered independent of assigned treatment.
Over a 26-week period, the total Mean (SD) cost of MRU per patient was £4325
(7143). For patients experiencing none, 1, or >1 PulmEx, total costs were £2587
(5446), £9318 (8196) and £10385 (8889), respectively. The total Mean cost of a
PDPE (£6731) was derived as the difference in MRU for medications, community
visits and hospitalisations between patients experiencing none (£689; £53; £1845)
or 1 (£1697; £57; £7565) PulmEx, respectively.
Reducing PulmEX is of signiﬁcant clinical, humanistic and economic value to
patients, providers and payers.
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CF related low bone mineral density (CFRLBMD) is deﬁned by a z-score at the
lumbar spine and/or hip <2 SD below the age and gender matched mean.
Objectives:
1. To determine the prevalence of CFRLBMD in patients at the All Wales Adult
CF centre
2. To review the demographics of patients with CFRLBMD
3. To review vitamin D levels, calcium supplementation and bisphosphonate therapy
in patients with CFRLBMD.
Methods: Bone densitometry scan results were reviewed for all patients and the
notes reviewed for those with CFRLBMD as deﬁned above.
Results: 53 (29 male) of the 252 patients reviewed had CFRLBMD (21%). Their
mean (SD) age, FEV1% and BMI were 26.9 (5.9) years, 43.7 (20.2)% and 21.3
(2.7) kg/m2 respectively. The mean vitamin D ug/L was 25.1 (12.1) with 21 (40%)
achieving a vitamin D over 30 (as recommended). Of the 53 patients 17 were on
long term oral steroids, 8 had evidence of renal dysfunction, two were smokers. 9
had impaired glucose tolerance and 29 had CF related Diabetes. Of the 53 patients
with CFRLBMD 48 (91%) were receiving calcium supplementation and 39 (74%)
bisphosphonate therapy. Of those 39 receiving bisphosphonates 16 (41%) had
received more than 5 years bisphosphonate therapy without a break and 16 were
females of childbearing age. 4 patients had documented fractures (2 rib, wrist,
metatarsal).
Conclusion: CFRLBMD is present in a ﬁfth of our patients with a preponderance
in diabetics and those on long term steroids. The majority of patients don’t
achieve recommended vitamin D target and almost three quarters are maintained
on bisphosphonates which are not currently licensed for CFRLBMD and the effects
of which in reproductive age females are as yet unclear.
